New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
05:22 EDTPSTIPluristem Therapeutics receives patent in India
Pluristem Therapeutics announced it has been granted Patent No. 261087 from India's Office of the Controller General of Patents, Designs & Trade Marks for a patent titled, "Methods for Cell Expansion and Conditioned Media Produced Thereby for Therapy." The patent, which has also been granted to Pluristem in Australia, Russia and South Africa, covers the company's key technology platform, its method for 3-dimensional expansion of placental and adipose derived cells. It also covers the composition of cells derived using this method.
News For PSTI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 27, 2014
05:26 EDTPSTIPluristem PLX-RAD cells to be studied at Case Western Reserve University
Pluristem Therapeutics announced that researchers at Case Western Reserve University will conduct a preclinical study of the Company's PLacental expanded-RAD, or PLX-RAD, cells. The study will evaluate whether PLX-RAD cells increase the success rate of human umbilical cord blood transplantation. Umbilical cord blood cells are transplanted to replace a patient's unhealthy bone marrow cells. When successful, a transplant can treat bone marrow failure, which can result from immune system disorders, genetic diseases, and leukemia treatment. When cord blood cells are administered to a patient, they travel to the bone marrow and produce healthy white and red blood cells and platelets after the patient's own abnormal cells have been eliminated. Sometimes, however, the cord blood cells fail to take hold and the transplant fails. The study at Case Western Reserve will research the feasibility of using PLX-RAD cells to help the cord blood to engraft more effectively, resulting in higher rates of successful transplantation and treatment. PLX-RAD cells are also being studied by the U.S. National Institutes of Health, NIH, for the treatment of acute radiation syndrome, or ARS, which involves bone marrow failure after exposure to high levels of radiation, as can happen after a nuclear catastrophe.
October 21, 2014
05:09 EDTPSTIPluristem moves to large-scale manufacturing after second product line completed
Pluristem Therapeutics announced that it has completed development of its second major product line, and can now begin manufacturing the cells on a large-scale at its state-of-the art facility in order to meet demand for anticipated studies in a range of hematologic conditions. This second cell product candidate, called PLX-RAD, was created using Pluristem's proprietary three dimensional cell expansion technology platform. The company's first product, PLX-PAD, is already in clinical trials for the treatment of peripheral artery disease, muscle injury and pulmonary arterial hypertension. Pluristem's development plan for the PLX-RAD cells considers numerous potential clinical indications such as: enhancement of engraftment of transplanted hematopoietic stem cells for the treatment of bone marrow deficiency, which can result from immune system disorders, genetic diseases, and treatment of leukemia and other blood cancers; treatment of bone marrow deficiency in patients who have undergone chemotherapy; treatment of acute radiation syndrome, or ARS in conjunction with the U.S. National Institutes of Health's National Institute of Allergy and Infectious Diseases.
October 20, 2014
07:19 EDTPSTIIBC Life Sciences to hold a conference
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use